WALDW — Waldencast plc

Summary of Waldencast Q1 2025 Earnings Call

1. Key Financial Results and Metrics

• Net Revenue: $65.4 million, a decline of 4.1% year-over-year.
• Adjusted Gross Profit Margin: 76.4%, up 10 basis points from the previous year.
• Adjusted EBITDA: $4.4 million, representing a margin of 6.7%.
• Milk Makeup Revenue: Declined 15.1%, with strong domestic performance offset by international challenges.
• Obagi Medical Revenue: Increased 7.1% to $36.2 million, despite out-of-stock issues.
• Cash Position: $10.8 million, with an additional $22.5 million available on a revolving credit facility.
• Net Debt: Increased to $172.1 million from $154.2 million, primarily due to refinancing costs.

2. Strategic Updates and Business Highlights

• Brand Growth Initiatives: Focus on elevating Milk Makeup and Obagi Medical through innovation, expanded distribution, and community engagement.
• Milk Makeup: Successful launch of Hydro Grip Gel Skin Tint, generating $18 million in earned media value and sold out shortly after release. Entry into Ulta Beauty has shown promising results.
• Obagi Medical: Continued focus on supply chain transformation to enhance operational efficiency and support growth.
• Digital Growth: Both brands experienced growth in digital channels, with Obagi's performance improving as they transitioned to a first-party e-commerce model.

3. Forward Guidance and Outlook

• Revenue Growth Target: Mid-teens growth for the full year.
• Adjusted EBITDA Margin: Expected to be in the mid to high-teens.
• Key Growth Drivers: Continued innovation, expansion in retail and digital channels, and improved product availability anticipated by the end of Q2.

4. Challenges and Points of Concern

• Supply Chain Issues: Both brands faced out-of-stock situations due to restructuring and inventory adjustments, impacting sales.
• International Performance: Milk Makeup struggled internationally due to tough year-over-year comparisons and delayed product launches.
• Macro Environment: Potential pressures from softer consumer sentiment and spending, with tariffs impacting cost of goods, though manageable.
• Declining Metrics: Milk Makeup's revenue decline and challenges in the physician channel for Obagi were noted, with less favorable comparisons to the previous year.

5. Notable Q&A Insights

• Supply Chain Restructuring: Management is focused on improving supply chain flexibility and responsiveness to meet demand, which has been a challenge in Q1.
• Physician Channel Performance: No significant slowdown in demand was observed; rather, a lack of tailwinds from last year's Amazon business transition was cited as a reason for slower growth.
• Pricing Strategy: Management is monitoring tariff impacts and is prepared to implement selective price increases if necessary, with a low to mid-single-digit range being considered.
• Ulta Beauty Launch: Early results from the Ulta partnership are positive, indicating potential for further expansion within Ulta's network.

Overall, while Waldencast faced challenges in Q1 2025, particularly with supply chain disruptions and revenue declines in certain areas, the company remains optimistic about its growth strategies and future performance.